Testosterone Treatment Articles
July 4, 2017. By Gordon Gibb.
Chicago, IL: AbbVie Inc., the makers of AndroGel, have garnered the lion’s share of attention (and the highest proportion of lawsuits) in the testosterone side effects MDL to date. However Eli Lilly and Co. (Lilly), the manufacturer of Axiron, is the subject of renewed focus after the federal judge in Illinois overseeing multidistrict litigation last month selected the first two bellwether cases that will go to trial next year (In re: Testosterone Replacement Therapy Products Liability Litigation, Case No: 1:14-cv-01748, in the US District Court for the Northern District of Illinois).Read [ Eli Lilly & Co. Testosterone Bellwether Trials Scheduled for 2018 ]
May 9, 2017. By Gordon Gibb.
Philadelphia, PA: Testosterone side effects associated with the usage of testosterone supplements and gels have, up until now, focused on cardiovascular issues. But now there is new research that suggests there is a cognitive price to pay.Read [ Testosterone Gels Get a Failing Grade in More Ways Than One ]
March 31, 2017. By Gordon Gibb.
Philadelphia, PA: As testosterone side effects lawsuits continue to roll in, a study published last month in JAMA (Journal of the American Medical Association) appears to confirm long-held assertions that testosterone therapy in otherwise healthy men serves only to increase the risks for heart attack and stroke needlessly.Read [ Latest Study Suggests AndroGel Increases Arterial Plaque in Older Men ]
February 26, 2017. By Gordon Gibb.
Chicago, IL: With the US and Canada remaining both direct neighbors and close trading partners, the Canadian equivalent to the US Food and Drug Administration (FDA) often mirrors safety updates issued by the FDA for drugs and medications. In specific cases, the Canadian position is in some measure more aggressive than its US counterpart. However when the FDA, in October of last year updated warnings to testosterone side effects inherent to testosterone supplements, Health Canada chose not to follow suit.Read [ While FDA Suggests Potential for Testosterone Abuse, Health Canada Takes a Pass ]
January 24, 2017. By Gordon Gibb.
Chicago, IL: Plaintiffs in testosterone lawsuits against defendant AbbVie Inc. found themselves momentarily distracted from the allegations at hand earlier this month when the Illinois federal judge overseeing multidistrict litigation over testosterone side effects needed to rule on a motion submitted by the defendant to trim a report from an expert witness in the case.Read [ Testosterone Defendant Attempts to Limit Scope of Expert Witness ]
November 23, 2016. By Heidi Turner.
Washington, DC: As plaintiffs in testosterone lawsuits wait for the testosterone side effect litigation to move forward, the US Food and Drug Administration (FDA) has announced it has approved new labeling changes that will affect all prescription testosterone therapies. The new testosterone labels affect both the Warning and the Abuse and Dependence sections of the drugs' label.Read [ FDA Announces New Testosterone Warnings ]
October 26, 2016. By Lucy Campbell.
Santa Clara, CA: All prescription testosterone products will now carry class-wide labeling changes introduced by The U.S. Food and Drug Administration (FDA) to warn of the health risks associated with testosterone abuse and dependence.Read [ Prescription Testosterone Products Get New FDA Health Warnings ]
October 17, 2016. By Gordon Gibb.
Chicago, IL: A manufacturer of a testosterone replacement therapy (TRT) based in Belgium recently petitioned to escape a testosterone lawsuit, given that the pharmaceutical company has little exposure, knowledge or influence over the US market. However, a federal judge in Illinois would have none of it.Read [ Belgian AndroGel Manufacturer Attempts to Duck Testosterone Lawsuits ]
September 1, 2016. By Heidi Turner.
Chicago, IL: For the men who filed testosterone lawsuits alleging they suffered serious side effects as a result of testosterone therapy, news that litigation is moving forward will be welcomed. Eight bellwether cases have been chosen and an initial trial date set for 2017. Claims surrounding testosterone therapy include allegations the therapy is linked to an increased risk of myocardial infarction and venous thromboembolism.Read [ Testosterone Bellwether Trials Chosen ]
August 4, 2016. By Gordon Gibb.
Washington, DC: There has never been any debate as to the effectiveness and usefulness of testosterone supplementation for a small cohort of men, for whom supplements can be vitally important. And testosterone therapy isn’t new, having been around for some time (with full blessing from the US Food and Drug Administration) as a treatment for hypogonadism, a condition characterized by severely low levels of testosterone that can lead to severe health problems. For those patients, any risk for testosterone side effects are deemed to be acceptable in view of the benefits for this particular segment of the patient population.Read [ Testosterone’s Benefit is Reversed in Robust Marketing to the Wrong Patient ]